Indiana University and PharmatrophiX Present Findings on Performance of Oral Therapeutic, LM11A-31, to Reduce Decline of Brain Functional-Network Connectivity in Alzheimer’s Disease
New findings presented at featured research session (FRS) during the Alzheimer’s Association International Conference demonstrate statistically significant slowing of decline…
PharmatrophiX Selected for Landmark UCSF-led platform trial in rare neurodegenerative disease; Unveils New Data at Tau Global Conference
PharmatrophiX unveiled preclinical data at the Global Tau Conference further supporting evidence that LM11A-31 is a multi-action shield for the…
Targeting Upstream Neurodegeneration: LM11A-31 in Alzheimer’s Disease and PSP
David Setboun, Pharm.D., MBA, CEO of PharmatrophiX, and Frank M. Longo, MD, PhD, Co-founder & Chairman, discuss LM11A-31’s upstream mechanism…
A better Alzheimer’s drug?
Stanford Medicine profiles LM11A-31 as a synapse-protective approach to slowing neurodegeneration.
p75 receptor modulation slows biomarkers and preserves visuospatial function
CTAD coverage reports p-tau217 and synaptic-proteome signals over 26 weeks.
New drug candidate targeting synaptic resilience well tolerated in Alzheimer’s patients
NIA summarizes safety and biomarker findings supporting larger LM11A-31 trials.
p75 neurotrophin receptor modulation in mild to moderate Alzheimer’s disease
The 26-week Phase 2a trial met its primary endpoint for safety and tolerability, with biomarker and imaging signals supporting further…
Targeting Endogenous Mechanisms of Brain Resilience in Alzheimer’s Disease
JPAD review frames p75NTR as a tractable resilience pathway for neurodegeneration.
Alzheimer’s from a New Angle
Dr. Frank Longo on hope, innovation, and a radical departure from traditional Alzheimer’s research
Dr. Frank Longo wins inaugural Melvin R. Goodes Prize
ADDF recognized Longo’s pioneering Alzheimer’s drug discovery work.